Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma

Glioblastoma (GBM) is inevitably refractory to surgery and chemoradiation. The hope for immunotherapy has yet to be realised in the treatment of GBM. Immune checkpoint blockade antibodies, particularly those targeting the Programme death 1 (PD-1)/PD-1 ligand (PD-L1) pathway, have improved the progno...

Descripción completa

Detalles Bibliográficos
Autores principales: Adhikaree, Jason, Moreno-Vicente, Julia, Kaur, Aanchal Preet, Jackson, Andrew Mark, Patel, Poulam M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072315/
https://www.ncbi.nlm.nih.gov/pubmed/31973059
http://dx.doi.org/10.3390/cells9020263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072315/
https://www.ncbi.nlm.nih.gov/pubmed/31973059
http://dx.doi.org/10.3390/cells9020263

Ejemplares similares